Last reviewed · How we verify

Romidepsin + CHOP — Competitive Intelligence Brief

Romidepsin + CHOP (Romidepsin + CHOP) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HDAC inhibitor + chemotherapy combination. Area: Oncology.

phase 3 HDAC inhibitor + chemotherapy combination Histone deacetylases (HDAC) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Romidepsin + CHOP (Romidepsin + CHOP) — The Lymphoma Academic Research Organisation. Romidepsin inhibits histone deacetylases to promote cancer cell death, combined with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) for multi-modal lymphoma treatment.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Romidepsin + CHOP TARGET Romidepsin + CHOP The Lymphoma Academic Research Organisation phase 3 HDAC inhibitor + chemotherapy combination Histone deacetylases (HDAC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HDAC inhibitor + chemotherapy combination class)

  1. The Lymphoma Academic Research Organisation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Romidepsin + CHOP — Competitive Intelligence Brief. https://druglandscape.com/ci/romidepsin-chop. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: